




PORTFOLIA

Dear FemTech Fund Investors -

Please find the highlights of Q3 2021 below, as provided by the companies. As a gentle reminder, by accessing this report, you agree to hold all non-public information in the strictest confidence. Portfolia companies in which we invest in are leading in highly competitive markets. All non-public information must be held confidential for the success of the companies. For any questions, please contact investments@portfolia.com. Thank you.

Company Updates

	<p>Future Family has completed their Series A-1 financing. The team has capitalized on the opportunity in the downturn with higher demand for fertility financing from customers and clinics. The team aims to work with debt partners to achieve 40% greater capital efficiency and strengthen unit economics with higher revenue per contract, lower cost of sale, and more efficient service/support layer.</p>
 primegenomics	<p>The team has extended their IP position and barriers to entry by filling two patent families (in review) and have completed their international fillings. They have extended their clinical program to two high volume clinical sites for patient enrollment and biobank development. Prime Genomics has secured a lead investor for their next equity financing.</p>
	<p>Madorra has completed their bridge round which will leverage their execution for a Series B round. Madorra has maintained a monthly burn rate of \$230k. The team has completed their Pilot Clinical Trial. The first participant completed her last visit in February, and March was spent quality checking the database. Madorra is now preparing to enroll in the Phase A cohort of their Pivotal Clinical Study. Their foundational patent was allowed in the European Union and now has allowed or granted patents in the US, Europe and Australia. CEO Holly Rockweiler is preparing for their Series B and is open to suggestions of who might be a good fit to lead the round.</p>

PORTFOLIA



Sana Health has closed another \$2M led by GreyHouse Partners with \$3M remaining. The team continues to focus on Fibromyalgia pivotal FDA study and preparation for 1,000 user study to test Fibromyalgia D2C willingness to pay. The tests are expected to start at the beginning of November. Sana is in early conversations with strategic partners. The team has sold 112 devices through their website without advertising. CEO Richard Hanbury is seeking introductions from potential investors or partners.



Bone Health Technologies has recently closed its Series A round. The team is halfway through a major clinical trial funded by \$2.2M of NIH grant funds, anticipate another \$2.7M NIH grant in Q2 of 2021, and expect to launch by summer of 2022.



The board has approved the second tranche closing for Aria CV. The FDA disapproved the Company's IDE application. The Aria team has already submitted a corrective plan for a few issues raised during the approval meeting (related to transport of devices by plane). The IDE was resubmitted in July and received FDA approval to begin human studies. The Chief Scientific Officer of Edwards fills the Board Observer role, and the team has also filled the Head Clinical PI.



Solace Therapeutics continues to perform well. The team is experiencing slow enrollment at this time due to Covid-19 but still have patients looking to enroll in clinical trials. The Board continues to work with the executive team to find ways to speed up enrollment. Solace's product continues to show good progress but still in the early phase. Expenses have been reduced and focused on enrollments to set up a call center to support enrollments.



Maven Clinic, now a unicorn company with a \$1.3B valuation, is partnering with Canada-based fertility services company, The Fertility Partners, to expand global access to Maven's platform, offering one-on-one guidance, education, and reimbursement assistance to members in 175 countries. Maven has recently released findings from a study that shares why pregnant people

PORTFOLIA

are hesitant to get COVID-19 vaccine. The Maven team will be offering free appointments with its OB-GYNs and midwives to answer questions and help educate pregnant people on the benefits of the COVID-19 vaccine.
